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Introduction
Alzheimer's disease (AD) is a slowly progressing neurodegenerative disorder that at present affects approximately 36 million people worldwide. Unless significant improvements for prevention and treatment can be found, the number has been estimated to rise to 115 million by 2050 (Wimo, et al., 2014) . The disease mechanism of AD is still not unraveled in detail; However, accumulation of beta-amyloid (Aβ) to extracellular plaques as well as the presence of soluble oligomeric forms (Aβ o ) have been suggested to be key events in the brain of AD patients, leading to other pathophysiological and neurotoxic changes, such as increased and spread tau pathology and synaptic dysfunction Selkoe, 2002,Karran and De Strooper, 2016) . Since the postulation of the amyloid cascade hypothesis 25 years ago (Hardy and Higgins, 1992) , there has been tremendous efforts to develop Aβ targeted compounds, aiming to either prevent excess formation of Aβ in the brain, or to remove already existing Aβ deposits, for disease modifying treatment of AD (Karran and Hardy, 2014) . Unfortunately, such compound has still not reached the market.
Non-invasive molecular imaging technique positron emission tomography (PET) is highly beneficial for research and drug discovery of CNS diseases, enabling the in vivo monitoring of various pathological processes, target engagement and treatment effects in human brain. For AD research, a positive amyloid PET scan obtained with Aβ binding radiotracers such as (Dubois, et al., 2014) , and can exploited in clinical Aβ-centric drug trials as an inclusion criterion for AD patients in addition to longitudinal monitoring of Aβ accumulation as a secondary outcome. Micro-PET imaging of Aβ pathology in transgenic (Tg) mouse models of the disease using [ 11 C]PIB and other Aβ-tracers provides an ideal translational in vivo method for preclinical proof-of-concept studies (Zimmer, et al., 2014) , and to date, changes in Aβ deposition have already been successfully followed in vivo using multiple mouse models of AD and different amyloid tracers (Brendel, et al., 2014 ,Maeda, et al., 2007 ,Manook, et al., 2012 M A N U S C R I P T
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4 2013, Snellman, et al., 2013 ,Snellman, et al., 2012 ,Zimmer, et al., 2014 . However, even though the potential advantages of longitudinal in vivo amyloid PET for preclinical drug development have been suggested by the authors, micro-PET imaging of Aβ has still mainly contributed to the characterization of novel PET radiotracers and animal models rather than Aβ-targeted drugs.
Nanotechnology and different functionalized nanomaterials offer a novel innovative approach for therapy of CNS diseases, often made challenging by limited penetration of drugs to the brain through the blood-brain barrier (BBB) (Re, et al., 2012) . Liposomes (LIPs) have been traditionally used as drug-carriers (Bozzuto and Molinari, 2015) , however, functionalized LIPs have recently been developed also as potential AD therapeutics (Balducci, et al., 2014 ,Bana, et al., 2014 ,Mancini, et al., 2016 ,Re, et al., 2011 . These LIPs are functionalized with two ligands, phosphatidic acid (PA) to bind Aβ (Gobbi, et al., 2010 ) and a modified peptide from the receptor-binding domain of apolipoprotein E containing amino acid residues 141−150 (mApoE) to increase BBB passage via the LDL receptor-mediated system . These LIPs, known as mApoE-PA-LIPs, have been seen to bind to Aβ 1-42 in vitro, inhibit its aggregation, promote the rupture of already existing deposits, and enhance the efflux of Aβ o in a BBB-model (Bana, et al., 2014 ,Mancini, et al., 2016 .
In subsequent in vivo studies, mApoE-PA-LIPs also decreased the amount Aβ 1-42 , Aβ o and Aβ deposits in the brain of APP-PS1 mice and significantly restored long-term recognition memory compared to a control group (Balducci, et al., 2014) . These observed in vivo effects have been suggested to be exerted partially by an enhancement of spontaneous Aβ efflux from the brain via a peripheral sink effect (Mancini, et al., 2016) .
The objective of this study was to validate the use of in vivo [ 11 C]PIB micro-PET imaging for following anti-Aβ treatment effects in preclinical studies by longitudinally evaluating the acute and long term effect of mApoE-PA-LIPs for cerebral Aβ deposition in the APP23 mouse model of AD.
Materials and Methods
Preparation and characterization of mApoE-PA-LIPs
Nanoliposomes known as mApoE-PA-LIPs were generated and characterized as described earlier (Balducci, et al., 2014) and were prepared freshly for each week of the study (n = 3). Cholesterol and sphingomyelin were obtained from Sigma-Aldrich (St. Louis, MO, USA), PA and Mal-PEG-PE from Avanti Polar Lipids, Ltd (Alabaster, AL, USA). The size of the LIPs was determined by dynamic light scattering before the mApoE functionalization and it was 190 ± 18 nm with a polydispersity index < 0.35. The lipid concentration of mApoE-PA-LIPs was 15.6 ± 0.5 mM based on sphingomyelin content. LIP functionalization with mApoE peptide residue was carried out as described by Re and co-workers (Larsen, et al., 1997) and converted online into [ 11 C]methyl triflate (Jewett, 1992) . After introducing the [ 11 C]methyl triflate into a solution of desmethyl precursor 6-OH-BTA-0 (0.6−1.0 mg) in acetone (200 µl) at 0 °C, followed by 3 min reaction at 80 °C, the product was purified in a HPLC column (YMC-Pack ODS-A, 5 µm, 10 × 250 mm, YMC Co.,Ltd., Japan) and a solid phase extraction C18 cartridge (Sep-Pak ® Light, Waters Corp., Milford, MA, USA). Ascorbic acid solution (Ascorell ® , 100 mg/ml, Sanorell Pharma GmbH, Germany) was used against radiolysis, that otherwise occurred during purification at specific activity (SA) levels over 1 TBq/µmol. For the HPLC mobile phase, Ascorell ® (2 ml) was added into 1 l of methanol/water (65:35 v/v). Solid phase extraction bulk dilution and washing solutions consisted of water (30 ml) and Ascorell ® (50 µl). The product was extracted from the cartridge by ethanol, diluted with propylene glycol/0.1 M phosphate buffer mixture (1.5:8.5, v/v) to a < 10% ethanol level and filtered through a sterile filter (Millex GV, 0.22 µm, 33 mm, Merck Millipore Ltd., 
Animals
Male (n = 10) and female (n = 2) APP23 Tg mice, aged 16−17 months were obtained from Novartis (Basel, Switzerland) . The APP23 mouse model expresses human APP751 with the Swedish double point mutation (K670M/N671L) driven by the neuron-specific mouse Thy-1.2 gene fragment as a promoter. Aβ immunoreactive plaques develop progressively starting from the frontal cortex (FC) and extending to the whole neocortex (NC) and hippocampus (HC) (Sturchler-Pierrat, et al., 1997) .
Mice were housed in individually ventilated cages, at an ambient temperature of 21 ± 3 °C and humidity of 55 ± 15%. Lighting and dark-cycles altered in 12 hr shifts starting at 6:00 a.m. Mice had ad libitum access to soya-free chow (SDS RM3 (E) soya-free, 801710; Special Diets Service) and tap water. Animals were sacrificed after the last PET scan by cardiac puncture in Isoflurane anesthesia. The animal study was approved by the National Animal Experiment Board of Finland. Figure 1 illustrates schematically the chronology of [ 11 C]PIB imaging and mApoE-PA-LIP treatment of APP23 mice. Mice were divided into two groups receiving either mApoE-PA-LIP (n = 5) or physiological saline (n = 7) as control. The separation of animals into two groups is described in Table 1 . Animals were allocated into saline and mApoE-PA-LIP groups to preserve the same mean age in each. As illustrated in Figure 1 , after initial [ (Balducci, et al., 2014) . APP23 mice over 15 months of age were used because they are known to have Aβ plaque formation already detectable by [ 11 C]PIB PET imaging (Snellman, et al., 2013) . The pre-defined brain areas of interest were the FC, NC and HC, based on the abundance of Aβ deposition in the APP23 model (Snellman, et al., 2013 ,Sturchler-Pierrat, et al., 1997 .
Experimental design
In vivo [ 11 C]PIB PET imaging
As illustrated in Figure 1 
Analysis of PET data
All data sets were analyzed without prior knowledge of the treatment status of the mice. The CB was used as the reference region because Aβ deposition does not occur in this region in APP23
mice (Sturchler-Pierrat and Staufenbiel, 2000) . Regional time-activity curves were calculated for each VOI, and [ 11 C]PIB binding was quantified as bound-to-free binding ratios for the late washout phase (40−60 min p.i.) as previously described (Snellman, et al., 2013) . Changes in binding ratios were calculated for follow-up intervals, as defined in Figure 1 .
Tissue collection
As indicated in Fig. 1 , after the last PET scan the brains from mApoE-PA-LIP (n = 4) and saline treated mice (n = 2) were dissected and the hemispheres were separated. The left hemisphere was frozen in chilled isopentane on dry ice, stored air-tight at −70 ºC and later cut into serial sagittal cryosections used for IHC. The right hemisphere was divided into the forebrain (without the olfactory system and brain stem) and CB, frozen in liquid nitrogen, and stored at −70º C for later preparation of brain homogenates for ELISA.
ELISA analysis
The right forebrain of each animal was homogenized in PBS, pH 7.4, containing protease inhibitors (Complete, Roche, Mannheim, Germany) and subjected to ultracentrifugation for 3 h (100,000×g).
The supernatant was collected and stored at −70º C prior to analysis as the PBS-soluble Aβ fraction. 
Thioflavin S staining and immunohistochemistry
The left hemisphere of each mouse was sliced longitudinally into 14 µm cryosections using ThS (Sigma-Aldrich, St. Louis, MO, USA) staining was carried out as described (Snellman, et al., 2012 ) and evaluated with a SteREO Lumar V12 microscope. Images were captured with an
Axiocam HRm camera (Zeiss, Jena, Germany). For quantification of Aβ load, microscope images with 10× (FC, NC) and 4× (HC) magnification were captured with use of an Olympus BX60 microscope and an Olympus DP71 camera (Olympus, Tokyo, Japan). 
Quantification of Aβ deposition
To estimate the area of ThS, Aβ 1-40 , and Aβ 1-42 stained Aβ plaques, serial microscope images from stained sections (0.5 mm intervals) of each APP23-mouse were obtained from different locations.
10× magnification was used in the FC (total 12 images per stain, from four sections) and NC (total 42 images per stain, from six sections), and 4× magnification for the HC (total six images per stain from, six sections). Images were transformed to 8-bit black-and-white images and the percentage of stained Aβ positive area from the total area was calculated using Image J 1.43u (Wayne Rasband, National Institutes of Health, MD, USA). The average percentages were calculated for each brain region.
Data analysis and statistics
Data are given as mean ± standard deviation (SD) or individual values if n < 3. The following calculations were carried out with use of GraphPad Prism software v. 5.01 (GraphPad Software, San Diego, CA, USA). Differences in injected doses, injected mass, SA, age and baseline binding ratios between mApoE-PA-LIP and saline groups were tested with unpaired t-test, and correlations between IHC and [ 11 C]PIB binding ratios with Pearson's correlation. Differences in changes in binding ratios over time between mApoE-PA-LIP and saline groups and differences in binding ratios over time within groups were tested using hierarchical linear mixed models where repeated measuring time points were handled as within factor and groups as between factor. This repeated measures analysis was performed with SAS®, v. 9.4 for Windows (SAS Institute Inc., Cary, NC, USA). Differences were considered statistically significant if p < 0.05 (two-tailed).
Results
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Animals and study deviations
During the longitudinal imaging study, three APP23 mice died before study termination: two male mice from the saline group during the treatment period and one male mouse from the mApoE-PA-LIP group during the follow-up period. These dropout animals did not show signs of illness or any abnormality at the time of imaging and thus the obtained data from these mice was included in the final analysis. The data points obtained from the dropout animals, and their effect on the obtained group means are clearly indicated in Fig. S1 . Brains from three saline treated mice (two females, one male) could not be used for histological or biochemical analysis due to technical difficulties.
Longitudinal in vivo [
C]PIB imaging
The baseline and follow-up [ After the three week period of treatment, as summarized in Table 2 Three months after termination of the mApoE-PA-LIP treatment, as seen in Table 2 [ 
Aβ deposition in the brain
All amyloid stainings revealed abundant Aβ deposition in the brain of both mApoE-PA-LIP and saline treated APP23 mice at follow-up 2. Large and ubiquitous ThS-fluorescent (Fig. 3 ) and anti-Aβ 1-40 -immunoreactive (Fig. 4 ) Aβ deposits were observed around the NC and HC in both groups.
Anti-Aβ 1-42 immunoreactive deposits ( (Fig. 6) .
Microglial activation in the brain
Iba-1 immunostaining, a marker for microglial activation, revealed abundant microgliosis around the brain in both mApoE-PA-LIP and saline injected APP23-mice. Most intense staining was seen to surround the existing Aβ deposits. Staining intensities were not quantified further; however, representative microscope images from the cortex, HC and CB are presented in Fig. S1 .
Discussion
Because of the increasing prevalence of AD, there is a strong need for both novel-disease modifying therapies, as well as improved methods that could benefit and speed up the drug development process. Here we report that treatment effects of nanoliposomes, known as mApoE-PA-LIPs, functionalized to bind and discard Aβ in the brain, were followed longitudinally in APP23 mouse model in vivo with use of micro-PET and amyloid PET tracer [ 11 C]PIB. We suggest that in addition to characterizing new PET tracers and animal models, micro-PET combined with mouse models of Aβ deposition would be a valuable tool for preclinical evaluation of novel anti-amyloid compounds for AD.
mApoE-PA-LIP treatment effects in APP23 mouse model of AD
The mApoE-PA-LIPs have previously been shown reduce Aβ pathology in vivo in APP/PS1 Tg mouse model (Balducci, et al., 2014) . In that model, peripheral administration of mApoE-PA-LIP M A N U S C R I P T
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14 led to decreased brain Aβ 1-40 , Aβ 1-42 and Aβ o levels, reduction in the number of Aβ plaques, and increase in plasma Aβ levels (Balducci, et al., 2014 ,Mancini, et al., 2016 . However, due to the low [ 11 C]PIB binding that has been previously reported in old APP/PS1 mice even with abundant histologically confirmed Aβ deposition (Snellman, et al., 2013) , this model could not be used for further [ 11 C]PIB PET imaging experiments and the APP23 model was exploited instead.
A pilot study, where [ 11 C]PIB PET was used to evaluate mApoE-PA-LIP effects in three APP23 Tg mice was included in the previously published study by Balducci and co-workers (Balducci, et al., 2014) . In that study, mApoE-PA-LIP-treated APP23 mice showed very low [ 11 C]PIB binding ratios similar to wild type mice at baseline (15 months), and interestingly also at both follow-ups, raising interest to further in vivo investigation of possible long term effects of mApoE-PA-LIP treatment.
Based on these results, we designed our study to include more animals, a proper control group receiving saline injections and similar additional follow-up period of three months after the termination of mApoE-PA-LIP administration. However, the [ 11 C]PIB PET imaging data presented here differs from the previously published results; In our study we saw a trend of slower increase in However, during the additional follow-up, [ 11 C]PIB retention increased significantly from baseline in both groups and equivalent immunohistochemically verified Aβ load was detected at study termination after follow-up 2. Thus, no long term differences between groups were detected.
In our study, the APP23 Tg mice were slightly older (16−17 months) at the initiation of the study and had higher quantified baseline reported by Mancini and co-workers (Mancini, et al., 2016 
Applicability of small animal [ 11 C]PIB PET for preclinical anti-amyloid drug development
Even though the first attempts to use [
C]PIB PET imaging for detecting cerebral Aβ deposition in
Tg mouse models resulted in contradictory results (Klunk, et al., 2005 ,Maeda, et al., 2007 , more recent studies have already demonstrated the usability of this method for non-invasive monitoring of histologically confirmed cerebral amyloidosis in various Tg mouse models, such as the APP23 mice (Maeda, et al., 2007 ,Snellman, et al., 2013 , APP/PS1 ARTE-10 mice (Manook, et al., 2012) and APP/PS1-21 mice (Maier, et al., 2014) . However, even after several studies confirming the usability of [ 11 C]PIB and other 18 F-labeled amyloid imaging PET tracers for preclinical imaging (Brendel, et al., 2015a ,Rominger, et al., 2013 ,Sérrière, et al., 2015 , to our knowledge, only one longitudinal study where a potential disease-modifying drug for AD was evaluated has been published to date (Brendel, et al., 2015b) . In this study, Brendel and colleagues showed that de novo plaque formation in APP-Swe mice was inhibited during treatment with a novel gamma-secretase modulator RO5506284, and the effect could be predicted by longitudinal in vivo [ 18 F]florbetaben micro-PET imaging (Brendel, et al., 2015b) . In our study, mApoE-PA-LIP treatment resulted in unchanged [ 11 C]PIB binding during the treatment in mApoE-PA-LIP group, in comparison to clear increase in the saline group, even though statistical significance could not be M A N U S C R I P T
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reached. However, high variability in [ 11 C]PIB binding ratios at baseline was detected in APP23 mice at this age, and consequently the group level differences in binding ratios over time did not reach statistical significance in any of the analyzed brain areas. Similar high variation in radiotracer binding at baseline that was seen in our study was also reported by Brendel and co-workers for the APP-swe model (Brendel, et al., 2015b) . The results from both of these studies clearly highlight the advantage of micro-PET and non-invasive longitudinal follow-up of anti-amyloid treatment effects in comparison to cross-sectional comparison of treatment and control groups: By longitudinal follow-up of PET tracer uptake in each animal it is possible to minimize the bias caused by high variation in Aβ levels even in age-matched Tg mice that have been reported for most mouse models of Aβ deposition. In addition, the method enables animal stratification based on their baseline binding ratios and estimated levels of Aβ pathology. For future studies this approach is highly recommended.
Study limitations
The lack of histological data verifying the level of Aβ deposition immediately after the mApoE-PA-LIP treatment period can be considered as a limitation of our study. However, after the final PET scan, Aβ load in the brain of Tg mice was quantified with ThS and IHC, and a positive correlation with the quantitated PET binding ratios was observed, further supporting the validity of brain [ 11 C]PIB retention as a biomarker for Aβ deposition in this Tg mouse model. Rather than a weakness, this could be seen as the benefit of in vivo PET methodology, where fewer animals are needed for producing high quality data with repeated in vivo measurements. In addition, as discussed before, longitudinal study design enables analyzing relative changes from baseline values, rather than sole differences between interventional and control groups after treatment, that most likely are affected by the considerable variation in the amount of Aβ deposition that has been reported for APP23 mice and most other Tg models (Sturchler-Pierrat, et al., 1997) .
The binding of mApoE-PA-LIPs to different forms of Aβ in vitro have been previously investigated by using Aβ 1-42 and its aggregates (Bana, et al., 2014 ,Gobbi, et al., 2010 ,Mancini, et al., 2016 , and thus the rationale of using the APP23 mouse model expressing more Aβ 1-40 than Aβ 1-42 for this study could be questioned. However, in the in vivo study by Balducci and colleagues, the mApoE-PA-LIP treatment was seen to decrease also soluble and insoluble Aβ 1-40 levels in the brain of APP/PS1 mice, suggesting that mApoE-PA-LIP binding is not restricted to Aβ 1-42 (Balducci, et al., 2014) . In addition, situation in human AD is similar to the APP23 model, as Aβ 1-42 comprises only 10% of the total Aβ levels (Hampel, et al., 2010) . Due to these reasons the usage of the APP23 model in our opinion is justified and future experiments with preventional study design and longer mApoE-PA-LIP treatment period including also another PET scan in the middle of the treatment would give more information about the Aβ clearing effects of mApoE-PA-LIPs in this model.
Recommendations for future studies
The study design presented here includes also parts that could be improved and should be carefully considered when planning future interventional small animal imaging studies. First, even though it was known that the used repeated measures analyses is more powerful than one time-point approach (unpaired t-test), the animal number in this study was still relatively low, and could be the reason for the difficulties in detecting significant treatment effects between the groups. To avoid this, sample size calculations should be performed also for preclinical studies to increase their translational value. If we would use the data from this study and plan a future study based on how the mApoE-PA-LIP treated mice behaved in the pilot study (Balducci, et al., 2014) , the mean baseline binding ratio of 0.4 could be estimated to remain unchanged at follow-up 2 in mApoE-PA-LIP group (SD was at greatest 0.25 for mApoE-PA-LIP group) and rise to 0.9 in the saline group
(SD was at greatest 0.33). If we then calculate the sample size with 80% power and 0.05 significance level (two-tailed), we end up with 7 mice per group. According to this information, our study was approaching the optimal sample size. However, as previously discussed, the mApoE-PA-M A N U S C R I P T
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18 LIP group did not behave as we expected based on the pilot study, as significant increases in the binding ratios were detected at follow-up 2. In addition, more animals should always be added to cover the possible dropouts during the study period that can be expected when aged AD models are used.
Second, animals with mixed gender were included, and both females were allocated to the saline group. Because the level of Aβ pathology has previously been reported to vary between male and female APP23 mice (Sturchler-Pierrat and Staufenbiel, 2000) , it would be ideal to include only males or females for intervention studies. However, in this study, the baseline binding ratios of the two female mice were seen to fit inside the observed variation in the male mice, and because repeated measurements were performed, the females were included to increase the relatively small sample size. Nevertheless, for future studies mixing genders is not be recommended.
Third, also the observed variation in the baseline binding ratios between age-matched groups was an unwanted finding in our study. For future studies, allocation of animals into groups based on their baseline binding ratios is highly recommended as an alternative to solely age-matching the groups. With this approach the groups could be better balanced and the accidental assignment of animals with very high or very low level of Aβ-pathology in one group could be avoided.
Conclusion
Shown here, the The dotted line connects the data obtained from the two individual mice illustrated in Fig. 2A . Age ( 
